|
|
News Breaks | | | | November 21, 2012 | | 17:03 EDT |  | MAPP | MAP Pharmaceuticals announces FDA acceptance of NDA resubmission
MAP Pharmaceuticals announced that its new drug application, or NDA, resubmission for LEVADEX orally inhaled migraine drug for the potential acute treatment of migraine in adults has been accepted for filing by the FDA. The FDA has classified the resubmission as a complete, Class 2 response to the FDA's March 26 action letter and has set a goal date of April 15, 2013 under the prescription drug user fee act. | |
|
News For MAPP From The Last 14 Days Check below for free stories on MAPP the last two weeks. |
|
|
| There are no results for MAPP |
|
|
|
|
|
|
